Logo-bma
Biomed adv. 2025;2(4): 183-194. doi: 10.34172/bma.39

Review Article

Engineering the ‘one-for-all’ cell: Molecular approaches to universal hypoimmunogenic pluripotent stem cells

Fatima Elmusa 1 ORCID, Nesibe Hande Imirzalioglu 2 ORCID, Mohammadreza Dastouri 3 * ORCID

Cited by CrossRef:



Acceptance Rate: 35%
Submission to First Decision: 20 Days
Received to Acceptance: 60 Days
Acceptance to Publication: 40 Days
*Average article statistics from the last 12 months of data.